New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.0000-0.0300 (-1.48%)
At close: 04:00PM EDT
2.1000 +0.10 (+5.00%)
After hours: 04:09PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 46.05M
Enterprise value -38.85M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.46
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.89

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-73.15%
S&P500 52-week change 3-4.45%
52-week high 38.5900
52-week low 31.2500
50-day moving average 31.8156
200-day moving average 32.4098

Share statistics

Avg vol (3-month) 3149.79k
Avg vol (10-day) 328.92k
Shares outstanding 523.56M
Implied shares outstanding 6N/A
Float 86.28M
% held by insiders 10.15%
% held by institutions 189.16%
Shares short (28 Jul 2022) 4105.59k
Short ratio (28 Jul 2022) 43.18
Short % of float (28 Jul 2022) 40.61%
Short % of shares outstanding (28 Jul 2022) 40.45%
Shares short (prior month 29 Jun 2022) 4123.91k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.26%
Return on equity (ttm)-40.38%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -44.09M
Net income avi to common (ttm)-44.27M
Diluted EPS (ttm)-1.8860
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)93.3M
Total cash per share (mrq)3.96
Total debt (mrq)5.99M
Total debt/equity (mrq)6.72
Current ratio (mrq)9.55
Book value per share (mrq)3.78

Cash flow statement

Operating cash flow (ttm)-38.76M
Levered free cash flow (ttm)-22.28M